Meeting Banner
Abstract #0149

Hyperpolarized [1-13C]/[5-13C] glutamate as a metabolic imaging marker of IDH1 mutant glioma response to temozolomide therapy

Elavarasan Subramani1, Chloe Najac1, Georgios Batsios1, Marina Radoul1, Pavithra Viswanath1, Abigail Molloy1, Donghyun Hong1, Anne Marie Gillespie1, Russell O. Pieper2,3, Joseph Costello2, and Sabrina M Ronen1,3
1Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, 2Department of Neurological Surgery, Helen Diller Research Center, University of California San Francisco, San Francisco, CA, United States, 3Brain Tumor Research Center, University of California San Francisco, San Francisco, CA, United States

Temozolomide (TMZ) is most commonly used for the treatment of primary glioblastoma but is now being considered for the treatment of low-grade glioma that harbor mutations in the cytosolic isocitrate dehydrogenase 1 (IDH1) gene. Though the treatment of IDH1 mutant patients with TMZ improves survival, there is a need for complementary metabolic imaging approaches to help in assessing early response to therapy. Hyperpolarized 13C magnetic resonance spectroscopy-based metabolic profiling of mutant IDH1 cells treated with TMZ revealed that [1-13C]/[5-13C] glutamate production from [1-13C] α-ketoglutaric acid/[2-13C] pyruvate could serve as translatable biomarkers of response to therapy.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here